RecruitingPhase 1NCT06608355
The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
Studying Atypical juvenile parkinsonism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- iRegene Therapeutics Co., Ltd.
- Intervention
- Human Dopaminergic Progenitor Cells(biological)
- Enrollment
- 6 enrolled
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Tongji Hospital Affiliated to Tongji Medical College Hust, Wuhan, Hubei, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06608355 on ClinicalTrials.gov